Ray Kurzweil
CIK: 0001108501
Associated companies
Transaction History
| UTHR | ▲ Buy | Option Exercise | 650 | $0 | 7/9/2026 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 4,910 | $500K | 3/4/2026 | View on chart |
| UTHR | ▼ Sell | Open Market | 4,910 | $2.4M | 3/4/2026 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 590 | $0 | 7/25/2025 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 15,000 | $2.6M | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 4,821 | $1.5M | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 1,303 | $415K | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 1,519 | $487K | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 100 | $32K | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 1,095 | $352K | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 2,256 | $713K | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 897 | $285K | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 2,259 | $710K | 2/28/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 750 | $242K | 2/28/2025 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 900 | $0 | 7/13/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 15,000 | $1.3M | 2/23/2024 | View on chart |
| UTHR | ▼ Sell | Other | 15,000 | $3.4M | 2/23/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 880 | $0 | 7/7/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 15,000 | $3.3M | 8/9/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 15,000 | $959K | 8/9/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 3,230 | $0 | 7/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
United Therapeutics Settles Litigation, Market Reassesses Valuation
United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.
United Therapeutics Settles Litigation, Market Reassesses Valuation. United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.